TickerTalks
Browse all tickers →
TickerTalks›$DARE
DADARE

Dare Bioscience, Inc.

$DARE·$21M·Biotechnology·Healthcare
$0.73-0.5%YTD-30.6%1Y-63.8%
Mentions · last 7 days
2026-08-21: 1 posts2026-08-22: 1 posts2026-08-23: 3 posts2026-08-24: 14 posts28+1%
Price updated 2d ago·X counts updated 6d ago
DADARE
$DAREDare Bioscience, Inc.
$0.74-0.50%28 posts+1%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $DARE, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-08-22

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

A microcap women's-health biotech that just closed a rescue financing at $1.37 — Nasdaq delisting risk is live.

Daré Bioscience is a small-cap women's-health biotech — commercial product XACIATO (bacterial vaginosis) plus a pipeline in contraception, menopause, HPV, and fertility. The company just closed a $6M dilutive financing to keep operating, and the equity is trading at just above $0.80.

  • The rescue financing is real dilution: 4.09M shares plus 294k pre-funded warrants at $1.37 in an at-the-market registered direct offering — that's the third or fourth capital-raise cycle for this micro-cap in the last twelve months, and each one dilutes existing holders further.
  • Nasdaq delisting risk is now a live catalyst: a July 17 8-K disclosed the company fell below the $2.5M stockholders' equity requirement, and Daré has requested a hearing before the Nasdaq Hearings Panel — a delisting to OTC would strand the equity outside institutional-buyer accessibility.
  • The commercial ramp is starting but tiny: revenue of $152K last quarter was up 500% year-over-year (off a tiny base), and Q4 2025 hit $1M — the multi-product women's-health strategy is real, but the numbers are microcap-scale for at least the next two years.
  • The consensus long-run trajectory implies survival first, then scale: FY26 revenue only $2.1M, FY27 $7.4M, FY28 $34.7M — that's the path to a real business, but only if the company survives the near-term dilution and delisting risk.

The stock sits at 2% of its 52-week range and 56% below the 200-day — this is a broken microcap in survival mode, coiling on the possibility that the multi-product ramp works before the equity runs out. The Nov 12 earnings print needs commercial-revenue growth to sequentially inflect above $500K and Nasdaq to resolve the equity-cure timeline. Continued sub-$1.00 tape and additional dilutive raises would confirm the breakdown; a fresh partnership or launched product with meaningful early sales breaks the coil higher. Retail readers should treat this as speculation, not investment.

Agrees with X sentimentX's +60% bounce framing is real (though days-old), and the multi-product strategy is a legitimate turnaround anchor. The crowd is under-weighting the Nasdaq delisting notice — that's a live existential risk on top of the dilution, and 'DCA adds' as a strategy on a delisting candidate is aggressive.

What to watch: Q3 earnings Nov 12: commercial revenue needs to sequentially inflect above $500K and the Nasdaq equity-cure timeline needs to be favorably resolved. Another dilutive raise or a Nasdaq delisting order would break the coil down.

On the calendar: 2026-11-12 — Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-08-20

Daré Bioscience posters are riding a sharp move. DARE jumped +60% and is still up +35% after-hours; the stock also did a stock offering that tanked it earlier, framed as a possible entry setup. Bulls flag two direct-sales products just launched in Q3 as a real ramp catalyst, and posters describe DCA adds as their preferred approach. 'This one has quietly become a standout, the kind of persistence that gets noticed.' Bullish.

Read the AI verdict + X sentiment for $DARE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biopharma developing contraception, fertility, and vaginal health products for women, with one FDA-approved drug (XACIATO).

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $DARE.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $DARE

Partial — medical device revenue depends on elective procedure volumes and hospital capex; Daré Bioscience, Inc.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-151%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-10.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-56.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
15.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
7.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
5.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
9.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.20$-0.30+32.6%
Q1 2026May 14, 2026$-0.20$-0.33+39.4%
Q4 2025Mar 26, 2026$-0.02$-0.24+91.7%
Q3 2025Nov 13, 2025$-0.28$-0.33+15.2%
Next earningsThu, Nov 12·consensus EPS $-0.14

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$152K+499.6%-423%-1967%$-0.21$-5.5M
Q4 FY25$1.0M-1708.4%71.1%-144%$-0.10$1.2M
Q3 FY25$2K-94.6%100%-162341%$-0.28$-617K
Q2 FY25$-21K-194.4%100%18080%$-0.45$-5.3M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.1M$1.5M – $2.8M-$0.95-$1.34 – -$0.562
FY27$7.4M$5.4M – $9.7M-$0.48-$0.68 – -$0.311
FY28$34.7M$24.1M – $45.2M$0.02$0.01 – $0.032
FY29$101.9M$74.5M – $134.2M$1.41$0.91 – $1.981
FY30$235.8M$172.2M – $310.5M$4.93$3.21 – $6.971

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.0%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-50.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-60.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 13.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.055-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 10 other (10 awards) in window

See when $DARE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

S-1Initial registrationAug 26S-1
AI summary

Daré Bioscience, Inc. (DARE, San Diego CA), a clinical-stage specialty biopharmaceutical company focused on women's reproductive and sexual health, filed a new S-1 registration statement with the SEC on August 26, 2026, with CEO Sabrina Martucci Johnson as agent contact and legal counsel Edwin Astudillo. The S-1 registers securities for a potential public offering, including the specific share count, offering price range, and use of proceeds detailed in the full document. This is a new capital markets registration (not an S-3 shelf), indicating DARE seeks to raise capital for clinical development. The filing represents a meaningful dilution event if the offering proceeds.

8-KMaterial agreementAug 178-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 8.01: Other event
AI summary

Daré Bioscience (DARE) filed an 8-K under Items 1.01, 3.02, 8.01, and 9.01, disclosing a material definitive agreement, issuance of unregistered securities, and other material events effective August 14, 2026. The combination of items indicates a financing transaction, likely a private placement or PIPE. No specific terms were available in the excerpt. Daré Bioscience is a San Diego, CA women's health therapeutics company.

424B5Prospectus supplement (offering)Aug 17424B5
AI summary

Daré Bioscience (DARE) filed a 424B5 prospectus supplement for an offering of 4,085,687 shares of common stock plus 293,894 pre-funded warrants at $1.37 per share ($1.3699 for pre-funded warrants). The pre-funded warrants include a 4.99%/9.99% ownership blocker, allowing investors approaching the threshold to use warrants instead of shares. The offering was part of a concurrent private placement. Daré Bioscience is a San Diego women's health company focused on novel drug delivery platforms.

8-KPress release / Reg FDJul 248-K — Item 7.01: Press release / Reg FD
AI summary

DARE filed an 8-K under Reg FD (Item 7.01), disclosing material non-public information simultaneously to all investors. The disclosure covers: presentation of Daré Bioscience, Inc. This is typically an investor presentation, conference slides, or press release furnished as an exhibit. Reg FD filings ensure equal access to information for all investors; the substantive data is in the attached exhibit.

8-KListing / delisting noticeJul 178-K — Item 3.01: Listing / delisting notice
AI summary

Daré Bioscience received a Nasdaq deficiency notice for falling below the minimum $2.5M stockholders' equity requirement for continued listing. The company has requested a hearing before the Nasdaq Hearings Panel, which automatically stays any delisting action until the hearing is resolved. Failure to restore its equity base could result in the company being delisted from Nasdaq.

8-KPress release / Reg FDJul 138-K — Item 7.01: Press release / Reg FD
AI summary

Daré Bioscience (DARE) — 8-K (Item 7.01) furnishing a corporate presentation as of July 13, 2026, to be used in meetings with investors and analysts per Regulation FD. The presentation covers Daré's pipeline and corporate strategy. Administrative — investor presentation filed for Reg FD compliance; no new material disclosures beyond pipeline information in the deck.

8-KPress release / Reg FDJun 228-K — Item 7.01: Press release / Reg FD
AI summary

Dare Bioscience, Inc. filed an 8-K under Reg FD on June 22, 2026 disclosing that it is using a corporate investor presentation (dated June 22, 2026, Exhibit 99.1) in meetings with securities market participants commencing that day. The presentation will be available on the company's IR website under Presentations. The content of the presentation is not included in the 8-K body. Routine Reg FD compliance filing for investor outreach — informational only, with no disclosed material corporate event.

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Daré Bioscience, Inc. held its 2026 Annual Meeting on June 11, 2026. Shareholders elected Class III directors Gregory W. Matz (3.75M for) and Sabrina Martucci Johnson (3.85M for); ratified Haskell & White LLP as auditor; approved amendments to the 2022 Stock Incentive Plan adding 1,500,000 shares; and voted on additional proposals per the April 28, 2026 proxy. The equity plan addition of 1.5M shares is mildly dilutive for this small-cap women's health biotech.

+ 30 other (8 8-Ks · 4 253G2s · 4 proxys · 3 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Seriesglobenewswire.com·4d agoDaré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcriptseekingalpha.com·4d agoDaré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Societyglobenewswire.com·5d agoDaré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segmentglobenewswire.com·6d agoDARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” Listglobenewswire.com·13d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport